-
St. Jude names Lori Spicer Robertson chief diversity, equity and inclusion officer
12/13/2022
Named as Memphis Business Journal’s 2022 Class of 40 Under 40, Spicer Robertson’s motto is ‘Live in your vision, not your circumstances.’ Read how this native Memphian and founder of the DEI Collective has made her way back to the Mid-South as the chief diversity, equity and inclusion officer of St. Jude Children’s Research Hospital.
-
St. Jude names Jasmine Plummer, Ph.D., as director of Center for Spatial Omics
12/06/2022
Dr. Plummer leads new program at St. Jude, exploring novel ways of measuring gene expression while preserving cellular organization.
-
Space and time influence G-protein coupled receptor interactions
12/05/2022
By simulating molecular dynamics, St. Jude scientists revealed how the selectivity or promiscuity of GPCR coupling relies on the location and duration of intermolecular interactions.
-
St. Jude research featured at the American Society of Hematology Annual Meeting
12/05/2022
Investigators will present research at the annual meeting of the American Society of Hematology, with findings from the St. Jude Lifetime cohort study.
-
James R. Downing, M.D., recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare
12/03/2022
St. Jude CEO James R. Downing MD is currently leading the $12.9 billion six-year strategic plan, the largest investment in its 60-year history to advance the study and treatment of pediatric cancer and other catastrophic diseases.
-
St. Jude ‘Wunderkind’ honored by STAT for work with synthesized organic molecules
11/16/2022
Daniel J. Blair, PhD, wins award for early-career scientists working on breakthrough discoveries in health, medicine and science.
-
‘Highly cited’ St. Jude scientists demonstrate influence in research
11/15/2022
The list is based on papers ranked in the top 1% by citations— how often a research paper is referenced by other investigators in their work.
-
Model demonstrates how RNA splicing defects contribute to Alzheimer’s disease
10/13/2022
St. Jude scientists studied the role of RNA splicing defects in Alzheimer’s disease, revealing degeneration and toxicity caused by neuron hyperexcitability.
-
Three of the world’s top research institutions join forces to drive progress against pediatric cancer
10/13/2022
The Broad Institute of MIT and Harvard, Dana-Farber Cancer Institute and St. Jude announced the largest academic collaboration of its kind.
-
A link between hypoxia and fetal hemoglobin provides hope for sickle cell disease
10/12/2022
Cellular response to low oxygen also increases fetal hemoglobin expression in adults, which could lead to novel treatments for some genetic anemias.
-
St. Jude early career researcher awarded NIH innovation grant
10/05/2022
Cell biologist Chi-Lun Chang, PhD, was awarded a 5-year $2.7 million grant to “push the boundaries of biomedical science.”
-
Health inequity may drive higher symptom burden in childhood cancer survivors
09/27/2022
Findings from St. Jude Children’s Research Hospital reveal that childhood cancer survivors with disadvantaged socio-demographic factors are over 7 times more likely to experience severe symptom burdens.
-
Findings explain exceptional auditory abilities in Williams-Beuren Syndrome
09/23/2022
St. Jude scientists identified the mechanism by which Williams-Beuren Syndrome enhances the ability to discriminate between sounds as interneuron hyperexcitability in the auditory cortex.
-
St. Jude finds a new way to identify ‘safe harbor’ for gene therapies
09/22/2022
A tool created by St. Jude scientists may increase the safety of gene and cell therapy by finding safe places to add genes to human DNA.
-
Rhombic lip implicated in origins of high-risk medulloblastoma
09/21/2022
St. Jude scientists found that group 3 and 4 medulloblastoma arise from the rhombic lip, knowledge that may help improve research models and therapeutic development.
-
St. Jude Comprehensive Cancer Center receives Merit Extension Award from NCI
09/16/2022
St. Jude Comprehensive Cancer Center award extends its current $35 million, five-year Cancer Center Support Grant (CCSG) for an additional two years.
-
St. Jude Environmental Services Department receives national recognition
09/13/2022
St. Jude department recognized for the first time with 2022 Environmental Services Department of the Year Award.
-
Family ties: Inherited genetic variants increase risk of Hodgkin lymphoma
09/08/2022
St. Jude scientists have completed the largest study of families affected by Hodgkin lymphoma and identified novel variants linked to cancer predisposition.
-
A near-death experience worsens some cancer cells
09/01/2022
Scientists at St. Jude Children’s Research Hospital discovered how some cancer cells survive treatment and cause cancer to recur, along with a potential way to stop the process.
-
To wipe childhood cancer off the map, scientists must chart its genomic landscape
09/01/2022
St. Jude scientists sequenced the most childhood cancer samples from a single cancer type ever in a landmark study.
-
SAFER Ukraine provides a blueprint for responding to global health crises
08/30/2022
St. Jude Global and partners help Ukrainian children with cancer and blood disorders continue treatment, creating a model for responses to other crises.
-
New chemical technology leads to better targeted therapeutics against high-risk leukemia in the lab
08/24/2022
St. Jude scientists created an LCK targeted PROTAC able to kill T-cell acute lymphoblastic leukemia cells.
-
Hiding in plain sight: Improved CAR T-cell therapy for T-cell acute lymphoblastic leukemia
08/05/2022
St. Jude scientists developed a simple method to select for more effective cancer-destroying CAR T cells to treat T-ALL.
-
Getting more mileage from a T-cell therapy for AML
07/28/2022
St. Jude scientists have created a proof-of-principle approach to improve engager T-cell therapy for difficult-to-treat acute myeloid leukemia.
-
Frank Fazio named president of Children's GMP and vice president of therapeutics production and quality at St. Jude
07/27/2022
The Good Manufacturing Practices (GMP) facility produces highly specialized biopharmaceuticals and other biological products for the hospital’s clinics.
-
Genetics weigh heavy on childhood cancer survivors’ risk of developing obesity
07/25/2022
St. Jude scientists created a way to identify childhood cancer patients at diagnosis who are at the highest risk for developing severe obesity as adults.
-
Study reveals a new therapeutic target for aggressive type of rhabdomyosarcoma
07/13/2022
Scientists at St. Jude found an Achilles’ heel in rhabdomyosarcoma driven by a gene fusion which revealed a promising treatment approach in the lab.
-
St. Jude Children’s Research Hospital announces expansion of its strategic plan to target pediatric catastrophic diseases
07/13/2022
Six-year plan will now commit $12.9 billion to support 2,300 jobs, among other priorities.
-
STEMM immersion program to shape the next generation of scientists
07/11/2022
St. Jude High School and College Research Immersion Program introduces science to a diverse group of students
-
Primary cilia in medulloblastoma: mechanisms provide treatment opportunity
07/07/2022
St. Jude scientists have shown how the presence or absence of primary cilia contribute to specific types of the most common malignant childhood brain tumor.
-
Researchers create a single-cell framework to potentially enhance CAR T–cell therapy
07/06/2022
St. Jude scientists developed a method that could improve CAR T-cell therapies by identifying the early cells that become effective at killing cancer.
-
Arkansas State Rep. Dwight Tosh honored at St. Jude for 60-year survival of childhood cancer
06/24/2022
Tosh is the first St. Jude patient to reach this milestone and was recognized at institution’s 60th anniversary celebration
-
St. Jude collaborates with multiple organizations to expand STEM opportunities in Memphis
06/23/2022
New collaboration with multiple organizations is part of national effort to provide equity in STEM education.
-
Pushing T cells down “memory lane” may improve cancer therapy
06/22/2022
St. Jude immunologists identified proteins that help decide T cell fate and used the finding to improve CAR-T cell therapy in a solid tumor model.
-
U.S. News & World Report ranks St. Jude as outstanding pediatric cancer hospital
06/14/2022
St. Jude Children’s Research Hospital recognized among hospitals delivering exceptionally high-quality care
-
A high-risk pair – a drug and DNA variant increase heart disease risk in cancer survivors
06/13/2022
St. Jude scientists identified a genetic difference in childhood cancer survivors treated with chemotherapy that predisposes them to heart problems as adults.
-
Unfreezing waters in ligand binding sites
06/07/2022
St. Jude scientists are studying how the temperature at which protein structures are captured can create "artifacts," – errors that cause misleading results.
-
St. Jude research highlighted at annual meeting of the American Society of Clinical Oncology
05/31/2022
Learn best practices and hear insights from St. Jude oncologists, psychologists and scientists at the annual gathering of clinical oncology experts.
-
Heterochromatin silencing is like a piano that doesn’t make a sound
05/31/2022
St. Jude scientists have a new understanding of the pathways that contribute to this gene silencing.
-
Killer T vs. memory – DNA isn’t destiny for T cells
05/20/2022
St. Jude scientists uncovered how one type of T cell creates two genetically identical, but functionally different, daughter cells.
-
Research reveals surprising inactivation mechanism for a voltage-gated ion channel
05/20/2022
This the first time researchers have identified the mechanism for closed-state inactivation. These approaches could be applied to other ion channels.
-
ZBP1 links interferon treatment and dangerous inflammatory cell death during COVID-19
05/19/2022
St. Jude scientists identified ZBP1 as a key contributor to the inflammatory cell death that drives morbidity and mortality in COVID-19 patients.
-
Updates on gene therapy for ‘bubble boy’ disease and cellular immunotherapy at ASGCT
05/12/2022
St. Jude scientists will discuss research on cellular therapies for pediatric cancer and more at the annual meeting.
-
A tool to unlock the ‘numbers game’ of big data in rare disease research
05/11/2022
Big data can cause big problems in rare disease genetics research. Scientists at St. Jude created a systematic solution to find the inherited genes contributing to rare disease.
-
Strategy overcomes EZH2 inhibitor resistance in SMARCB1 mutated cancer
05/09/2022
Findings from St. Jude demonstrate the role of chromatin regulation in cancer’s resistance to EZH2 inhibitors and offer a way to make treatment more effective.
-
Scientists reveal new cause of cancer
05/05/2022
The team looked at a poorly understood form of chronic leukemia, CLPD-NK. The results led the researchers to create a new model of cancer development.
-
Study shows how a potential new class of antibiotics works
05/02/2022
Scientists at St. Jude are studying antimicrobial compounds called argyrins. Argyrins have shown some success against a bacterium called Pseudomonas aeruginosa.
-
Lab findings suggest EGFR inhibitors may prevent rhabdomyosarcoma recurrence
04/27/2022
RMS is the most common soft tissue sarcoma in children. When it recurs after therapy, the survival rate is only 30%.
-
Single-molecule techniques illuminate mechanisms of GPCR activation
04/27/2022
St. Jude scientists and their Columbia University collaborators reveal how GPCR signaling is regulated with implications for drug development.
-
Study finds jumping “junk” DNA is a novel cause of childhood brain cancer
04/22/2022
St. Jude scientists have found the first known example of a promoter ‘donation’ event from a retrotransposon causing a highly malignant childhood brain cancer.
-
J. Paul Taylor, M.D., Ph.D., named scientific director and executive vice president of St. Jude
04/18/2022
Dr. Taylor steps into the role during a pivotal time of growth for St. Jude, as its scientific enterprise will significantly expand.
-
American Society of Clinical Oncology honors St. Jude clinical brain tumor researcher
04/12/2022
Dr. Amar Gajjar becomes the seventh St. Jude Children’s Research Hospital investigator to receive the Pediatric Oncology Award
-
Dr. Martine Roussel recognized for groundbreaking work
04/10/2022
The AACR also honored the St. Jude scientist for her contributions to advancing women in science.
-
St. Jude researchers honored for contributions to treatment of pediatric blood disorders
04/06/2022
St. Jude researchers are recognized by the American Society of Pediatric Hematology/Oncology for their expertise and career achievements
-
Immune responses support COVID-19 vaccination regardless of when people were infected
04/05/2022
St. Jude scientists have studied how vaccination before and after primary infections affect the immune response.
-
St. Jude at the American Association for Cancer Research Annual Meeting
03/30/2022
Scientists from St. Jude Children’s Research Hospital will participate in the annual gathering of a premier professional society for the cancer research community.
-
St. Jude Children’s Research Hospital evacuates second group of patients from Ukraine safely to United States
03/29/2022
Four more Ukrainian children with cancer and their 11 family members arrived at St. Jude Children’s Research Hospital in Memphis, Tennessee.
-
First Ukrainian pediatric cancer patients evacuated to U.S. arrive safely at St. Jude Children’s Research Hospital
03/22/2022
St. Jude continues to help move hundreds of Ukrainian children with cancer to safety so they can continue treatment.
-
James R. Downing, M.D., elected to Fellows of AACR Academy Class of 2022
03/22/2022
Dr. Downing is honored for his outstanding contributions and innovations in cancer research.
-
Chronologically young, biologically old – DNA linked to cancer survivors’ premature aging
03/22/2022
St. Jude Children’s Research Hospital findings lay the groundwork for identifying pediatric cancer survivors at higher risk of accelerated aging and chronic diseases.
-
Study has implications for developing universal flu vaccine
03/16/2022
St. Jude scientists have found a clue as to why our immune systems do not target virus components that all flu strains share.
-
Removing barriers to pediatric early warning systems
03/09/2022
PEWS are not widely used in hospitals with limited resources. To understand why, scientists at St. Jude conducted a study.
-
Memphis Airport to open unique lounge for St. Jude Children’s Research Hospital
03/07/2022
Private, comfortable space in newly designed airport concourse will be staffed by St. Jude employees.
-
With Fundacja Herosi, St. Jude aids Ukrainian children with cancer and blood disorders at Unicorn Marian Wilemski Clinic
03/06/2022
On Saturday, the Foundation’s building in Bocheniec, now officially named the Unicorn Marian Wilemski Clinic, welcomed the first group of Ukrainian children and their families. Read more about this ongoing effort.
-
St. Jude creates HPV cancer prevention awareness campaign to emphasize the need for HPV vaccination
03/04/2022
Emphasizing the need for HPV vaccination, the campaign launches March 4, 2022, International HPV Awareness Day.
-
Research reveals high-risk subtype of relapsed pediatric AML
02/17/2022
St. Jude scientists have found a previously overlooked mutation in a subtype of pediatric leukemia that has implications for identifying high-risk patients.
-
St. Jude leases interim office space in Peabody Place as campus grows
02/16/2022
The hospital relocates 500 administrative employees to the temporary workspace during the construction phase of its six-year strategic plan.
-
Research lays a foundation for prevention of the most common childhood cancer
02/07/2022
St. Jude scientists blocked development of acute lymphoblastic leukemia in mice with a genetic mutation that increases the risk of childhood cancer.
-
St. Jude Children’s Research Hospital celebrates 60 years of saving children’s lives
02/04/2022
Diamond jubilee events are planned nationwide for supporters to honor St. Jude visionaries, recognize expanding global impact of scientific, medical achievements
-
Young vs. old: How host environment affects immune response
02/04/2022
St. Jude scientists have shown that the active immune system in young hosts may actually work against cancer immunotherapies by exhausting T cells.
-
Inherited gene variant powers up an oncogene to drive a high-risk leukemia
02/03/2022
Scientists at St. Jude have revealed how an inherited genetic variant turns on an oncogene, increasing the risk of developing childhood leukemia. Published in Nature Genetics.
-
CAR T cells target AML, spare bone marrow
01/31/2022
St. Jude scientists created an immunotherapeutic strategy for a type of pediatric leukemia using CAR T cells that target a tumor-specific antigen.
-
Genetic ancestry provides important context for understanding global diversity in childhood leukemia
01/27/2022
St. Jude scientists show that addressing racial disparities in acute lymphoblastic leukemia should include considering how genetic ancestry affects biology and prognosis.
-
Common cold coronaviruses hinder antibody immune response to SARS-CoV-2 infection
01/12/2022
St. Jude study also suggests that prior immunity to common cold coronaviruses does not protect against SARS-CoV-2 infection.
-
Modular super-enhancer controls retinal development
01/11/2022
Scientists at St. Jude identified distinct functions for regions of a super-enhancer that controls gene expression during retina formation, calling it a ‘modular’ super-enhancer.
-
Understanding how autoactivation triggers cell death
01/11/2022
Scientists from St. Jude have captured the structure of autoactivated BAK, a key protein for triggering apoptosis in cancer cells.
